Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 1998

View Archived Issues

Company Profile: FibroGen

Cantab to acquire vaccine programs for addiction from ImmuLogic

Novel enzyme inhibitors from microbial source claimed by HMR as antidiabetics

Anti-IL-5R monoclonal antibodies and antagonists in development by Tanox

More CRF antagonists emerge from Janssen/Neurocrine Biosciences collaboration

Merck obtains option to expand MDX-447 collaboration with Medarex

U.S. clinical trials of SU-6668 slated for early 1999

Peripheral nerve regeneration enhanced by hyaluronic acid in rat model

Promising phase III trial results presented for Coulter's lead cancer therapy

Biodiversity-related grant awarded to Xenova Discovery

Resveratrol shown to bind to and cleave DNA

YM-872: neuroprotective effects in animal model indicate potential in acute ischemic stroke

Cardiovascular and Renal Drugs Advisory Committee meets in late January to discuss two NDAs

Vion pursues prodrugs of 3-AP with superior biological, pharmaceutical properties

First U.S. marketing approval for Cephalon: Provigil cleared for narcolepsy-associated EDS

Acquisition broadens Isis's antisense patent estate

Phase II trial results for Immune Response's therapeutic RA vaccine published

Synvisc cleared for marketing in several Pacific Rim countries

Grant to help Faulding and collaborators develop innovative prostate cancer treatment

Ono-4057 useful in organ transplants according to results presented at Japanese congress

Effects of TAK-044 in canine model of liver ischemia-reperfusion injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...